TRYPSIN SE (Pancreatin)

Neova Technologies Inc.

TRYPSIN SE (Pancreatin) is a protease complex, containing trypsin (EC 3.4.2 1.4), chymotrypsin (EC, pancreatic elastase (EC, and carboxypeptidase B (EC, obtained from the porcine pancreas by Neova Technologies Inc. 

Neova Technologies Inc. produces purified trypsin preparations from government-certified pork pancreas glands. Pancreatin contains naturally occurring pancreatic proteins that play an important role in the digestion of food. PANCREATIN is a pancreas extract containing most pancreatic enzymes. Pancreatin contributes to the digestion of proteins, lipids, and carbohydrates.


TRYPSIN SE (Pancreatin)is Neova’s unique preparation of pancreatin. This common commercial product has enzymatic activities including protease, amylase, and lipase.

TRYPSIN SE (Pancreatin) is prepared from pork pancreas glands.


Pharmaceuticals and Medical Food

TRYPSIN SE (Pancreatin) is used to treat digestive disorders by replacing digestive enzymes when the body is unable to produce them, such as liver or pancreas disease. It is also used to treat indigestion caused by diabetes. TRYPSIN SE is also suitable in medical-food and feeding bag production (tube-feeding).

Food Applications

TRYPSIN SE (Pancreatin) can be added to foods to improve digestibility and facilitate rapid absorption of nutrients. TRYPSIN SE (Pancreatin) can be added to infant and follow-on formulae as a protease ingredient to improve digestibility and facilitate fast absorption of nutrients,

Non Warranty: The information contained herein is provided in good faith and, to the best of our knowledge, is true and correct. However, no warranty or guarantee is implied or inferred and the information may be subject toì change without further notice. Neova Technologies Inc.’s products are sold with the understanding that the purchaser will conduct tests to determine the suitability of these products for their particular use.

Product properties
Latest News

Bioseutica® is proud to inform that the European Food Safety Authority (EFSA) has just issued its scientific opinions on two applications submitted by NEOVA Technologies Inc (a  BIOSEUTICA group company) related to the food enzymes

  • trypsin and chymotrypsin from porcine pancreas (our Brand name TRYPSIN VI)
  • trypsin, chymotrypsin, elastase and carboxypeptidase from porcine pancreas (our Brand name TRYPSIN SE)

The EFSA conclusions for the 2 enzymes are:
“Based on the origin of the food enzyme from edible parts of animals, the data provided by the applicant, supported by the evaluation of clinical studies with pharmaceutical preparations based on pancreatic enzymes, the Panel concluded that the porcine pancreatic enzymes do not give rise to safety concern under the intended conditions of use.”
Access to the 2 scientific opinions published on the EFSA Journal Vol. 19, No. 1, January 2021 is freely available here.
Based on these EFSA safety evaluations, the 2 food enzymes will be approved by the European Commission by means of their inclusion into the Union list of food enzymes, expected in 2023.
These positive opinions are a confirmation of the commitment the Bioseutica group has to the quality and safety of its products, as well as to our dedication to service to our customers and end-users.

Show in grid

More information